View Future GrowthCellyan Biotechnology 과거 순이익 실적과거 기준 점검 0/6Cellyan Biotechnology 의 수입은 연평균 -136.8%의 비율로 감소해 온 반면, Logistics 산업은 연평균 1.5%의 비율로 감소했습니다. 매출은 연평균 21.2%의 비율로 감소해 왔습니다.핵심 정보-136.76%순이익 성장률-130.71%주당순이익(EPS) 성장률Logistics 산업 성장률19.04%매출 성장률-21.24%자기자본이익률-13.65%순이익률-4.29%최근 순이익 업데이트30 Sep 2025최근 과거 실적 업데이트Reported Earnings • Mar 30First half 2025 earnings releasedFirst half 2025 results: EPS: US$0.083. Net income: US$828.6k (up US$828.6k from 1H 2024).모든 업데이트 보기Recent updatesNew Risk • Apr 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 21% over the past year. Shareholders have been substantially diluted in the past year (114% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$16.3m market cap).New Risk • Mar 29New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 114% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 21% over the past year. Shareholders have been substantially diluted in the past year (114% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$16.0m market cap).New Risk • Mar 19New major risk - Revenue and earnings growthRevenue has declined by 21% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 21% over the past year. Market cap is less than US$10m (US$7.25m market cap).New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (US$7.26m market cap). Minor Risk Latest financial reports are more than 6 months old (reported March 2025 fiscal period end).New Risk • Dec 03New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$8.57m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Market cap is less than US$10m (US$8.57m market cap).공시 • Aug 01Hong Kong Pharma Digital Technology Holdings Limited announced delayed 20-F filingOn 07/31/2025, Hong Kong Pharma Digital Technology Holdings Limited announced that they will be unable to file their next 20-F by the deadline required by the SEC.Valuation Update With 7 Day Price Move • Jul 31Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$1.08, the stock trades at a trailing P/E ratio of 6.2x. Average trailing P/E is 16x in the Logistics industry in the US.Valuation Update With 7 Day Price Move • Jul 01Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to US$1.19, the stock trades at a trailing P/E ratio of 6.9x. Average trailing P/E is 16x in the Logistics industry in the US.Valuation Update With 7 Day Price Move • Jun 03Investor sentiment improves as stock rises 32%After last week's 32% share price gain to US$1.58, the stock trades at a trailing P/E ratio of 9.1x. Average trailing P/E is 16x in the Logistics industry in the US.Valuation Update With 7 Day Price Move • May 19Investor sentiment improves as stock rises 19%After last week's 19% share price gain to US$1.29, the stock trades at a trailing P/E ratio of 7.4x. Average trailing P/E is 17x in the Logistics industry in the US.Valuation Update With 7 Day Price Move • May 01Investor sentiment improves as stock rises 23%After last week's 23% share price gain to US$1.19, the stock trades at a trailing P/E ratio of 6.9x. Average trailing P/E is 16x in the Logistics industry in the US.New Risk • Apr 19New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.97m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). High level of non-cash earnings (36% accrual ratio). Market cap is less than US$10m (US$9.97m market cap).New Risk • Apr 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). High level of non-cash earnings (36% accrual ratio). Minor Risk Market cap is less than US$100m (US$13.2m market cap).Valuation Update With 7 Day Price Move • Apr 14Investor sentiment improves as stock rises 17%After last week's 17% share price gain to US$1.27, the stock trades at a trailing P/E ratio of 7.3x. Average trailing P/E is 19x in the Logistics industry in the US.Reported Earnings • Mar 30First half 2025 earnings releasedFirst half 2025 results: EPS: US$0.083. Net income: US$828.6k (up US$828.6k from 1H 2024).Valuation Update With 7 Day Price Move • Mar 24Investor sentiment improves as stock rises 25%After last week's 25% share price gain to US$1.36, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 20x in the Logistics industry in the US.Valuation Update With 7 Day Price Move • Mar 07Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to US$1.36, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 21x in the Logistics industry in the US.Valuation Update With 7 Day Price Move • Feb 13Investor sentiment improves as stock rises 21%After last week's 21% share price gain to US$2.20, the stock trades at a trailing P/E ratio of 18.2x. Average trailing P/E is 22x in the Logistics industry in the US.Valuation Update With 7 Day Price Move • Jan 30Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to US$2.17, the stock trades at a trailing P/E ratio of 17.9x. Average trailing P/E is 24x in the Logistics industry in the US.매출 및 비용 세부 내역Cellyan Biotechnology가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqCM:HKPD 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비30 Sep 2516-12030 Jun 251802031 Mar 252002031 Dec 242112030 Sep 242122030 Jun 241922031 Mar 241712031 Mar 2313120양질의 수익: HKPD 은(는) 현재 수익성이 없습니다.이익 마진 증가: HKPD는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 HKPD의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: 현재 수익성이 없어 지난 1년간 HKPD의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: HKPD은 수익성이 없어 지난 해 수익 성장률을 Logistics 업계(-1%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: HKPD는 현재 수익성이 없으므로 자본 수익률이 음수(-13.65%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YTransportation 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/26 20:38종가2026/05/22 00:00수익2025/09/30연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Cellyan Biotechnology Co., Ltd는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Mar 30First half 2025 earnings releasedFirst half 2025 results: EPS: US$0.083. Net income: US$828.6k (up US$828.6k from 1H 2024).
New Risk • Apr 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 21% over the past year. Shareholders have been substantially diluted in the past year (114% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$16.3m market cap).
New Risk • Mar 29New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 114% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 21% over the past year. Shareholders have been substantially diluted in the past year (114% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$16.0m market cap).
New Risk • Mar 19New major risk - Revenue and earnings growthRevenue has declined by 21% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 21% over the past year. Market cap is less than US$10m (US$7.25m market cap).
New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (US$7.26m market cap). Minor Risk Latest financial reports are more than 6 months old (reported March 2025 fiscal period end).
New Risk • Dec 03New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$8.57m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Market cap is less than US$10m (US$8.57m market cap).
공시 • Aug 01Hong Kong Pharma Digital Technology Holdings Limited announced delayed 20-F filingOn 07/31/2025, Hong Kong Pharma Digital Technology Holdings Limited announced that they will be unable to file their next 20-F by the deadline required by the SEC.
Valuation Update With 7 Day Price Move • Jul 31Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$1.08, the stock trades at a trailing P/E ratio of 6.2x. Average trailing P/E is 16x in the Logistics industry in the US.
Valuation Update With 7 Day Price Move • Jul 01Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to US$1.19, the stock trades at a trailing P/E ratio of 6.9x. Average trailing P/E is 16x in the Logistics industry in the US.
Valuation Update With 7 Day Price Move • Jun 03Investor sentiment improves as stock rises 32%After last week's 32% share price gain to US$1.58, the stock trades at a trailing P/E ratio of 9.1x. Average trailing P/E is 16x in the Logistics industry in the US.
Valuation Update With 7 Day Price Move • May 19Investor sentiment improves as stock rises 19%After last week's 19% share price gain to US$1.29, the stock trades at a trailing P/E ratio of 7.4x. Average trailing P/E is 17x in the Logistics industry in the US.
Valuation Update With 7 Day Price Move • May 01Investor sentiment improves as stock rises 23%After last week's 23% share price gain to US$1.19, the stock trades at a trailing P/E ratio of 6.9x. Average trailing P/E is 16x in the Logistics industry in the US.
New Risk • Apr 19New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.97m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). High level of non-cash earnings (36% accrual ratio). Market cap is less than US$10m (US$9.97m market cap).
New Risk • Apr 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). High level of non-cash earnings (36% accrual ratio). Minor Risk Market cap is less than US$100m (US$13.2m market cap).
Valuation Update With 7 Day Price Move • Apr 14Investor sentiment improves as stock rises 17%After last week's 17% share price gain to US$1.27, the stock trades at a trailing P/E ratio of 7.3x. Average trailing P/E is 19x in the Logistics industry in the US.
Reported Earnings • Mar 30First half 2025 earnings releasedFirst half 2025 results: EPS: US$0.083. Net income: US$828.6k (up US$828.6k from 1H 2024).
Valuation Update With 7 Day Price Move • Mar 24Investor sentiment improves as stock rises 25%After last week's 25% share price gain to US$1.36, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 20x in the Logistics industry in the US.
Valuation Update With 7 Day Price Move • Mar 07Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to US$1.36, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 21x in the Logistics industry in the US.
Valuation Update With 7 Day Price Move • Feb 13Investor sentiment improves as stock rises 21%After last week's 21% share price gain to US$2.20, the stock trades at a trailing P/E ratio of 18.2x. Average trailing P/E is 22x in the Logistics industry in the US.
Valuation Update With 7 Day Price Move • Jan 30Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to US$2.17, the stock trades at a trailing P/E ratio of 17.9x. Average trailing P/E is 24x in the Logistics industry in the US.